H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on VERV stock, giving a Buy rating yesterday.
Mitchell Kapoor has given his Buy rating due to a combination of factors surrounding Verve Therapeutics’ VERVE-102. The anticipated positive data from the Phase 1b (Heart-2) trial, expected in the second quarter of 2025, plays a significant role in this rating. The trial aims to demonstrate the efficacy of VERVE-102 in reducing LDL and PCSK9 levels in patients with HeFH and ASCVD, with safety data showing no treatment-related serious adverse events so far.
Additionally, the design improvements in VERVE-102, compared to its predecessor VERVE-101, offer potential safety advantages. The use of a validated ionizable lipid in its LNP design, sourced from Novartis, and the addition of a GalNAc component for better liver targeting, further support the confidence in its safety and efficacy. These factors, along with the cleared IND filing and the expansion to U.S. sites, contribute to Kapoor’s positive outlook and Buy rating for Verve Therapeutics.